

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, DC 20549

**FORM 8-K**

**CURRENT REPORT PURSUANT  
TO SECTION 13 OR 15(d) OF THE  
SECURITIES EXCHANGE ACT OF 1934**

Date of report (Date of earliest event reported): **March 18, 2022**

**KIORA PHARMACEUTICALS, INC.**

(Exact name of registrant as specified in its charter)

**Delaware**

(State or other jurisdiction of incorporation)

**001-36672**

(Commission File Number)

**98-0443284**

(IRS Employer Identification No.)

**1371 East 2100 South  
Suite 200**

**Salt Lake City, Utah 84105**  
(Address of principal executive offices)

**84105**  
(Zip Code)

**(781) 788-9043**

(Registrant's telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

| <u>Title of each class:</u>    | <u>Trading Symbol(s)</u> | <u>Name of each exchange on which registered:</u> |
|--------------------------------|--------------------------|---|
| Common Stock, \$0.01 par value | KPRX                     | The Nasdaq Capital Market                         |

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

On March 18, 2022, Michael Meluzio resigned as the Corporate Controller of Kiora Pharmaceuticals, Inc. (the "Company") to pursue other opportunities. Mr. Meluzio had served as the Company's principal financial officer and principal accounting officer on an interim basis beginning on February 25, 2022. Mr. Meluzio's resignation did not result from any disagreement regarding the Company's operations, policies or practices.

Effective as of March 18, 2022, Brian M. Strem, Ph.D., the Company's President and Chief Executive Officer, was appointed as the Company's principal financial officer and principal accounting officer. The Company has engaged Danforth Advisors, LLC to provide interim finance and accounting services until a permanent replacement is found.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

**KIORA PHARMACEUTICALS, INC.**

By: /s/ Brian M. Strem, Ph.D.  
Brian M. Strem, Ph.D.  
President and Chief Executive Officer

Date: March 23, 2022

---